The rising landscape of Indian pharmaceuticals is witnessing significant interest on Retatrutide, a new dual GIP and GLP-1 target exhibiting efficacy for obesity treatment . This peptide here is generating considerable buzz within the pharmaceutical community, particularly as domestic companies pursue commercialization agreements . The current situ